title: [Long-term response to eribulin in patients with metastatic breast cancer-report of 2 cases].
abstract: Case 1: Case 1 involved a 42-year-old woman who had been diagnosed as having advanced breast cancer (Stage III B). She had previously received 6 courses of cyclophosphamide, epirubicin, and 5-fluorouracil CEF, 14 courses of weekly paclitaxel, and 2 courses of vinorelbine( VNR). After the courses of chemotherapy, she underwent modified radical mastectomy with axillary lymph node dissection. Two years after surgery, lung metastases were found, and the patient received 6 courses of weekly paclitaxel and 13 courses of nab-paclitaxel. However, the lung metastases progressed after the courses of chemotherapy, and therefore, we decided to administer eribulin as third-line chemotherapy. Eribulin was effective against the lung metastases for more than 1 year. Case 2: Case 2 involved a 52-year-old woman who had been diagnosed as having Stage IIB breast cancer. She had received 4 courses of CEF and 4 courses of docetaxel as neo-adjuvant chemotherapy. After chemotherapy, she underwent breast-conserving surgery with axillary lymph node dissection. Five years postoperatively, multiple liver metastases were found, and the patient received 3 courses. However, the liver metastases progressed after this chemotherapy. Subsequently, we administered nab-paclitaxel; however, it produced severe side effects. We then decided to administer eribulin as second-line chemotherapy. Eribulin was effective against the liver metastases for more than 1 year.
authors.affiliation: Division of Breast and Endocrine Surgery, Dept. of Surgery, Nihon University School of Medicine.
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Hara
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sakurai
authors.forename: Saki
authors.initials: S
authors.lastname: Nagashima
authors.forename: Shuhei
authors.initials: S
authors.lastname: Suzuki
authors.forename: Eiko
authors.initials: E
authors.lastname: Waga
authors.forename: Kyoko
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Mio
authors.initials: M
authors.lastname: Hagiwara
authors.forename: Tetsuyo
authors.initials: T
authors.lastname: Maeda
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Hirano
authors.forename: Katsuhisa
authors.initials: K
authors.lastname: Enomoto
authors.forename: Mayumi
authors.initials: M
authors.lastname: Tani
authors.forename: Sadao
authors.initials: S
authors.lastname: Amano
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D013997:Time Factors; D000095662:Polyether Polyketides
chemical_list: D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides